10-Q: Tenax Therapeutics Q3 Loss Widens Amid R&D Surge

Tenax Therapeutics reported a significant increase in net loss for Q3 and the nine months ended September 30, 2025, driven by expanded clinical trial activities and higher operating expenses, while maintaining sufficient cash for operations through 2027.

Summary

• Net loss for the three months ended September 30, 2025, was $15.8 million, a 299% increase from $4.0 million in the same period of 2024.
• Net loss for the nine months ended September 30, 2025, was $37.1 million, a 227% increase from $11.3 million in the same period of 2024.
• Research and development (R&D) expenses surged by 232% to $10.3 million for the three months and 173% to $22.1 million for the nine months ended September 30, 2025, primarily due to the Phase 3 LEVEL trial and LEVEL-2 study start-up.
• General and administrative (G&A) expenses increased by 330% to $6.5 million for the three months and 336% to $17.8 million for the nine months ended September 30, 2025, largely due to non-cash stock-based compensation and increased capital market expenses.
• Cash and cash equivalents stood at $99.4 million as of September 30, 2025, up from $94.9 million at December 31, 2024.
• Management projects sufficient capital to fund operations through 2027.
• The company continues to advance its Phase 3 LEVEL study for levosimendan (TNX-103) in PH-HFpEF and plans to initiate a second global Phase 3 study, LEVEL-2, this year.
• An amendment to the Simdax license agreement on September 3, 2025, granted exclusive worldwide rights for oral levosimendan products and manufacturing rights for subcutaneous products, with Orion supplying the active pharmaceutical ingredient.

Sentiment

Score: 4

Explanation: While the company reported significantly increased losses and cash burn due to expanded clinical trial activities, it also demonstrated progress in its Phase 3 levosimendan program and secured sufficient liquidity to fund operations through 2027. The long-term capital needs and the inherent risks of drug development temper the positive operational updates.

Positives

• Cash and cash equivalents increased to $99.4 million as of September 30, 2025, from $94.9 million at December 31, 2024.
• Management believes the company has sufficient funds to continue operations through 2027.
• Patient enrollment in the Phase 3 LEVEL study continues with high rates of study and therapy continuation.
• The company is on track to commence the second global Phase 3 study, LEVEL-2, this year.
• Secured exclusive worldwide rights for oral levosimendan products and manufacturing rights for subcutaneous products through a September 3, 2025, license amendment with Orion Corporation.
• Interest income significantly increased by 227% to $2.9 million for the nine months ended September 30, 2025, due to higher cash deposits and increased interest rates.

Negatives

• Net loss for the three months ended September 30, 2025, increased by 299% to $15.8 million compared to $4.0 million in the prior year period.
• Net loss for the nine months ended September 30, 2025, increased by 227% to $37.1 million compared to $11.3 million in the prior year period.
• Accumulated deficit grew to $351.9 million as of September 30, 2025.
• Operating expenses significantly increased, with R&D up 173% to $22.1 million and G&A up 336% to $17.8 million for the nine months ended September 30, 2025.
• Net cash used in operating activities more than doubled to $22.4 million for the nine months ended September 30, 2025, from $11.3 million in the prior year period.
• Net cash provided by financing activities decreased substantially to $26.9 million for the nine months ended September 30, 2025, from $99.8 million in the prior year period.
• A significant portion of cash balances, $98.8 million, was uninsured by the FDIC as of September 30, 2025.

Risks

• Future equity raises will cause significant dilution to stockholders.
• Debt financings may incur significant interest expense and subject the company to restrictive covenants.
• Collaboration and licensing arrangements may require relinquishing rights to technologies or product candidates on unfavorable terms.
• The company expects to continue incurring significant expenses and operating losses for the foreseeable future.
• Uncertainty exists regarding the duration and completion costs of current or future clinical stages of product candidates.
• The probability of success for each product candidate and clinical trial is affected by various factors, including early clinical data quality, investment, competition, manufacturing, and commercial viability.
• The ability to continue product development beyond 2027 depends on obtaining license income, warrant exercises, or outside financial resources, with no assurance of success.
• The Simdax license can be terminated by either party if no US regulatory approval for the Product is granted by September 20, 2030.
• Cash balances of $98.8 million were uninsured by the FDIC as of September 30, 2025.

Future Outlook

The company expects to continue incurring significant expenses and operating losses for the foreseeable future as it advances levosimendan through Phase 3 clinical trials (LEVEL and LEVEL-2) and potentially develops imatinib. Management believes current capital is sufficient through 2027, but substantial additional capital will be required beyond that for commercialization and further development, which may come from license income, warrant exercises, or outside financing, though there is no assurance of securing these resources. Patient enrollment for the LEVEL study is expected to conclude in the first half of 2026, and the LEVEL-2 trial is on track to commence this year.

Management Comments

• "We intend to use the net proceeds from the March 2025 Offering to advance our Phase 3 oral levosimendan program, by completing our ongoing Phase 3 LEVEL study of TNX-103 in pulmonary hypertension resulting from heart failure with preserved ejection fraction (PH-HFpEF) and initiating a second global Phase 3 study, LEVEL-2."
• "Patient enrollment in our Phase 3 LEVEL study continues, with high rates of study and therapy continuation during the blinded and open-label extension stages. We expect to enroll 230 patients in the first half of 2026."
• "We remain on track to commence LEVEL-2 this year."
• "Given our resources on September 30, 2025, we believe we can continue our operations through 2027."
• "We will continue to incur losses until we generate sufficient revenue to offset our expenses, and we anticipate that we will continue to incur net losses for at least the next several years."
• "We will need substantial additional capital in the future in order to finalize the development of levosimendan, commence its commercialization, potentially develop imatinib, and to continue with the development of other potential product candidates."

Industry Context

Tenax Therapeutics operates in the highly capital-intensive and high-risk pharmaceutical industry, specifically targeting cardiopulmonary diseases like pulmonary hypertension. The strategy of repurposing already-approved drugs like levosimendan and imatinib, which have established safety profiles, is a common de-risking approach in drug development. However, the significant increase in R&D expenses reflects the substantial investment required for late-stage clinical trials (Phase 3), a critical and costly phase for any pharmaceutical company aiming for market authorization. The global expansion of trials (LEVEL-2) indicates a broader market ambition, aligning with trends for therapies addressing widespread conditions.

Comparison to Industry Standards

• The company's strategy of developing levosimendan and imatinib, both previously approved for other indications, aligns with a de-risked approach often seen in smaller biotech firms, contrasting with larger pharmaceutical companies that might pursue novel compounds from early discovery.
• The substantial increase in R&D expenses for Phase 3 trials is typical for a development-stage pharmaceutical company advancing a lead candidate.
• The accumulated deficit and continued net losses are standard for companies in this stage, as revenue generation from product sales is contingent on successful clinical development and regulatory approval.
• The need for additional capital beyond 2027 is a common characteristic of biotech companies with late-stage pipelines, as commercialization efforts and further pipeline development require significant funding.

Management Changes

Corporate Governance

Legal Proceedings

• No material pending legal proceedings to which the company is a party or to which any of its property is subject.

Stakeholder Impact

• Shareholders: Experience dilution from past and potential future equity raises. Face increased losses and cash burn, but also potential upside from clinical trial progress.
• Employees: Benefit from increased stock-based compensation and additional performance-based compensation, reflecting growth in employee numbers and compensation adjustments.
• Customers (future): Potential for novel cardiopulmonary therapies (levosimendan, imatinib) to improve lives of patients with pulmonary hypertension.
• Creditors: No significant debt mentioned, but future debt financings could introduce restrictive covenants.
• Suppliers (Orion Corporation): Orion benefits from milestone payments and royalties from the Simdax license agreement, and will supply levosimendan API.

Next Steps

• Complete patient enrollment for the Phase 3 LEVEL study (expected in the first half of 2026).
• Initiate the second global Phase 3 study, LEVEL-2 (on track for this year, 2025).
• Submit marketing authorization applications following completion of the two Phase 3 trials of levosimendan.
• Submit marketing authorization application for imatinib following completion of a single Phase 3 trial, when appropriate.
• Continue to identify and develop other potential product candidates.
• Seek additional capital beyond 2027 through license income, warrant exercises, or outside financing.

Key Dates

Recommendation

The company is in a critical, high-risk development stage with significantly increased operating losses and cash burn, which is typical for a biotech firm advancing Phase 3 trials. While the cash position is currently sufficient through 2027 due to recent capital raises, substantial additional funding will be required thereafter, posing a significant future dilution risk. The progress in the LEVEL study and the planned initiation of LEVEL-2 are positive operational developments, but the success of these trials and subsequent regulatory approvals are highly uncertain. Given the increased financial risk balanced by clinical progress and near-term liquidity, a 'hold' recommendation is appropriate for investors already exposed, awaiting further clinical data and clarity on long-term financing strategies before making further commitments.

Keywords

Tenax Therapeutics, TENX, 10-Q, Quarterly Report, Pharmaceutical, Cardiopulmonary Therapies, Levosimendan, PH-HFpEF, Pulmonary Hypertension, Clinical Trials, LEVEL Study, LEVEL-2 Study, Imatinib, Drug Development, Biotechnology, SEC Filing, Financial Results, Operating Loss, Cash Position, Liquidity, Stock-based Compensation, Orion Corporation, License Agreement